Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy

Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy

BackgroundFailure to CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), is an emerging clinical problem. There is no consensus on the treatment for these patients and treatment remains empirical.Case Repor...

Full description

Bibliographic Details
Main Authors: Weiguo Zhu, Shi Tao, Wenchun Miao, Hui Liu, Xianggui Yuan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
diffuse large B-cell lymphoma
chimeric antigen receptor T cell
chidamide
zanubrutinib
histone deacetylase inhibitor
Bruton’s tyrosine kinase inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.894787/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.894787/full

Similar Items